**Cancer Stem Cells and Tumour-initiating Cells**

- Cancer Stem Cells (CSCs) are defined by three properties:
  - Tumour initiation capacity,
  - Self-renewal and
  - Differentiation. (Ward and Dirks 2007).
- Current approaches to identify human CSCs include: phenotypic or functional purification, *in vitro* assays to measure self-renewal, differentiation and signaling pathways through sphere-forming assays, or *in vivo* assays to study self-renewal in serial recipients and analyze their histological phenotype (Figure 1).

---

**Figure 1.** Experimental approaches for the study of human cancer stem cells (CSCs). Human tumours are dissociated and may be in vitro cultured or injected in vivo after phenotypic or functional purification. The self-renewal activity of CSCs can be evaluated by serially culturing in colony-forming or sphere-forming assays, or by the serial transplantations into recipient mice. CSCs should regenerate a tumour phenotypically representative of the cancer from which it was sampled. In vitro and in vivo approaches may be combined in order to evaluate other CSCs characteristics, like differentiating potential, survival, proliferation, genetics and functionality of molecular pathways.
Two models try to explain tumour origins and progression of tumours.

- The cancer stem cell model (CSC) model assumes that only a very small subset of cells within the tumour population actually has the capacity to initiate and sustain tumour growth (Figure 2a).
- The stochastic model assumes that every cancerous cell has the capacity to extensively proliferate and regenerate a tumour but the probability of this event is low (Figure 2b). The model predicts that isolating discrete populations of cancer cells based on functional or phenotypic characteristics cannot enrich the tumour-initiating capacity.
a. Cancer stem cell model or hierarchical model

CSC

Differentiated tumor cells

b. Stochastic model
In the hematopoietic system, it has been proposed that one intermediate HSC (pre-leukemia HSC) can harbour some, but not all, leukemia-specific mutations accumulated during a prolonged “pre-leukemic” phase (Figure 3).

Lapidot et al. in 1994 demonstrated that cells CD34⁺CD38⁺ from acute myeloid leukemia (AML) patients could be injected into severe combined immunodeficient (SCID) mice to generate a leukemia phenotype (Lapidot et al. 1994).

Years later, this serially transplantable population of human leukemia cells from AML patients enriched from tumour-initiating abilities was called leukemia stem cells (LSCs). Its further characterisation revealed a functional hierarchy (Bonnet and Dick 1997).

The first identification of a cancer stem cell population in solid tumours was made in breast as CD44⁺CD24⁻/lo. Lineage, that was enriched in tumour-initiating ability when injected into NOD/SCID mice and serially transplanted into recipients.

Analysis of tumours demonstrated the presence of a heterogeneous population of cells similar to that of the original tumour (Al-Hajj et al. 2003).

Additional markers have been proposed to make the difference between CSCs from normal cells, CD133 is one of them, this surface marker is expressed in the minority of cultured tumour cells. In vitro, a subfraction of CD133⁺ cells formed tissue spheres whereas CD133⁻ did not.

Like normal stem cells, CSC can be isolated on the basis on their ability to efflux Hoechst33342 (a DNA-binding fluorescent dye).

In HSCs, Hoechst is excluded from the stem cell population within a short time after incubation through export protein pumps. Hoechst<sup>low/⁻</sup> fraction included stem cells and is also called side population (SP). (Goodell et al.).

On the other hand, aldehyde dehydrogenase (ALDH) is also found in stem cells and can be useful to identify their simile population in cancer. ALDH<sup>⁺</sup> cells have been isolated from cancer breast, liver, colon, pancreas, prostate, lung, ovarian and leukemia where stemness comes together with high enzyme activity.

The identification of CSCs based on their metabolic state is a promising research field still in progress where CSCs maintain low ROS levels exhibiting redox patterns that are similar to the corresponding normal stem cells.

Anticancer therapies targeting the bulk tumour do not eliminate stem cells and it may lead to
Figure 3. Model of pre-leukemic evolution of leukemia. Malignant transformation is a process requiring a progressive accumulation of mutations. Normal hematopoietic stem and progenitor cells are represented as cells with absence of mutations or damage. The first mutation may target a HSC or a more differentiated cell inducing the retention or acquisition of the self-renewal potential. Every time a new mutation appears, there is the possibility that results lethal for the cells or after a period of derives in clone depletion due to immune surveillance or competition with normal hematopoiesis. Eventually, after the accumulation of sufficient mutations (N) a leukemic stem cell (LSC) or leukemic initiating cells (LIC) is generated. The resultant leukemic cell loses the capability to differentiate into multiple cellular lineages and leads to the progression of the disease. [Corces-Zimmerman and Majeti, 2014 by J.C. Balandrán and J. Enciso.]

Quiz

Now test your knowledge with these questions!

References and Links


Immunopaedia.org.za


